Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
Immix Biopharma, Inc. (IMMX)
Company Research
Source: GlobeNewswire
– On track for first FDA Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – Los Angeles, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that 50% enrollment milestone has already been surpassed in NEXICART-2, its relapsed/refractory AL Amyloidosis clinical trial of sterically-optimized CAR-T NXC-201. Immix continues to enroll expediently toward BLA submission. “With excitement generated by our clinical results presented at ASCO, surpassing 50% enrollment in NEXICART-2 demonstrates the growing interest among relapsed/refractory AL Amyloidosis clinicians and patients, where no drugs are FDA approved today,” said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immi
Show less
Read more
Impact Snapshot
Event Time:
IMMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMMX alerts
High impacting Immix Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
IMMX
News
- Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch [Yahoo! Finance]Yahoo! Finance
- Immix Biopharma appoints Michael Grabow as chief commercial officer to drive NXC-201 launch [Seeking Alpha]Seeking Alpha
- Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 LaunchGlobeNewswire
- Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025GlobeNewswire
- Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation ConferenceGlobeNewswire
IMMX
Sec Filings
- 12/2/25 - Form EFFECT
- 11/26/25 - Form 8-K
- 11/7/25 - Form 10-Q
- IMMX's page on the SEC website